CLPT (ClearPoint Neuro) Other Current Liabilities: $4.14 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLPT ClearPoint Neuro Inc CLPT
63 GF Score
Price $15.16
GF Value $14.14
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is ClearPoint Neuro Other Current Liabilities?

ClearPoint Neuro CLPT +1.95% 63 Other Current Liabilities is $4.14 Mil as of Jun. 2026. GuruFocus rates CLPT with a GF Score™ of 63/100 and a GF Value™ of $14.14 (Fairly Valued). The stock has 8 warning signs investors should review.

ClearPoint Neuro's other current liabilities for the quarter that ended in Jun. 2026 was $4.14 Mil.

ClearPoint Neuro's quarterly other current liabilities declined from Dec. 2025 ($4.36 Mil) to Mar. 2026 ($2.98 Mil) but then increased from Mar. 2026 ($2.98 Mil) to Jun. 2026 ($4.14 Mil).

ClearPoint Neuro's annual other current liabilities increased from Dec. 2023 ($2.95 Mil) to Dec. 2024 ($4.89 Mil) but then declined from Dec. 2024 ($4.89 Mil) to Dec. 2025 ($4.36 Mil).

ClearPoint Neuro Other Current Liabilities Related Terms

ClearPoint Neuro Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for ClearPoint Neuro's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClearPoint Neuro Other Current Liabilities Chart

ClearPoint Neuro Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.60 2.82 2.95 4.89 4.36

ClearPoint Neuro Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.95 3.52 4.36 2.98 4.14
CLPT
63GF Score
ClearPoint Neuro Inc CLPT
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ClearPoint Neuro Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $4.14 Mil mean?
ClearPoint Neuro (CLPT) has a Other Current Liabilities of $4.14 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on ClearPoint Neuro.
Is ClearPoint Neuro's Other Current Liabilities too high?
ClearPoint Neuro's current Other Current Liabilities is $4.14 Mil. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's Other Current Liabilities compare to SI and PACB?
ClearPoint Neuro's Other Current Liabilities of $4.14 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on ClearPoint Neuro. ClearPoint Neuro's current Other Current Liabilities is $4.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $15.16 — trading 7.2% above its estimated fair value. The current Other Current Liabilities is $4.14 Mil. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current Other Current Liabilities is $4.14 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ClearPoint Neuro (CLPT) Overvalued in 2026?

Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued. The current stock price of $15.16 is trading 7.2% above its estimated GF Value™ of $14.14. GuruFocus considers ClearPoint Neuro to be Fairly Valued.

Key valuation signals for CLPT:

  • Other Current Liabilities: $4.14 Mil
  • GF Value™: $14.14 vs. price of $15.16 (7.2% above fair value)
  • GF Score™: 63/100 with 8 warning signs

No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ClearPoint Neuro Business Description

Address 120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score

Get the complete analysis for CLPT

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.16
Price
$14.14
GF Value